Statements (22)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:pharmaceuticals
|
gptkbp:approves |
gptkb:FDA
|
gptkbp:atccode |
L01 XX40
|
gptkbp:can_be_combined_with |
gptkb:capecitabine
gptkb:trastuzumab |
gptkbp:casnumber |
1234567-89-0
|
gptkbp:chemical_formula |
C22 H24 N4 O3 S
|
gptkbp:clinical_trial |
Phase 2
Phase 3 |
https://www.w3.org/2000/01/rdf-schema#label |
Tukysa
|
gptkbp:ingredients |
tucatinib
|
gptkbp:manufacturer |
gptkb:Seattle_Genetics
|
gptkbp:marketed_as |
gptkb:2020
|
gptkbp:route_of_administration |
oral
|
gptkbp:side_effect |
fatigue
nausea diarrhea rash liver problems |
gptkbp:used_for |
treatment of breast cancer
|
gptkbp:bfsParent |
gptkb:Genzyme_Genetics
|
gptkbp:bfsLayer |
6
|